Important Scientific Correction

First, the original draft described HEP-1 as an organ-specific liver bioregulator with hepatocyte-repair, detoxification, oxidative-stress, and healthy-aging effects. For example, those claims are not supported by the established HEP-1 literature.

However, the documented compound is:

Meanwhile, Human Ezrin Peptide 1, a synthetic peptide corresponding to amino acids 324–337 of the human ezrin protein.

Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu

TEKKRRETVEREKE

Moreover, researchers have investigated it mainly as an antiviral and immunomodulatory peptide, including work involving HIV-related immune suppression, hepatitis C virus, gastrointestinal ulcer models, and COVID-19.

What Is HEP-1?

First, HEP-1 is a synthetic, highly charged 14-amino-acid peptide modeled on a segment of the human cytoskeletal protein ezrin. It is also described in some literature as human ezrin peptide 1 or as an active component associated with the product name Gepon in Eastern European and Russian-language sources.

Next, ezrin belongs to the ERM protein family—ezrin, radixin, and moesin—which links the plasma membrane to the actin cytoskeleton and participates in immune-cell activation, receptor organization, cell adhesion, membrane trafficking, and viral entry or assembly.

🧬 Molecular Structure

First, HEP-1 is a linear, non-amidated tetradecapeptide containing many lysine, arginine, and glutamate residues. It is therefore strongly charged and highly hydrophilic.

🧪 Amino-Acid Sequence

H-Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu-OH

One-letter notation:

TEKKRRETVEREKE

⚛️ Molecular Weight and 🧫 Formula

Therefore, the apparent molecular weight of supplied material may differ because of acetate, trifluoroacetate, chloride, water, or other counterions. Meanwhile, a certificate should state whether assay is calculated on an anhydrous, salt-free, or “as is” basis.

📅 Discovery Timeline

1990s: Ezrin-fragment immunology research begins

First, patents and experimental work described a peptide from the central α-helical region of human ezrin as a possible modulator of immune responses in HIV-associated immune suppression and opportunistic infection.

1995: Early international patent filings

Next, patent literature disclosed the 14-residue human ezrin peptide sequence and proposed anti-infective and immune-modulating uses.

2000s: Broader infectious-disease and gastrointestinal research

Moreover, additional patents and regional reports explored HEP-1 in bacterial, fungal, viral, respiratory, and ulcer-related conditions.

2004–2014: Hepatitis C research

In addition, ezrin-, radixin-, and moesin-derived peptides were studied for interference with hepatitis C virus infection, entry, or replication. Likewise, a peptide identified as Hep-1/HEP-1 showed antiviral activity in cell models.

2020–2022: COVID-19 trials and patents

Meanwhile, researchers repurposed HEP-1 for studies in SARS-CoV-2-positive patients. In addition, a randomized trial was registered, and patents described use in acute and post-COVID settings.

Current status

Finally, HEP-1 remains outside established U.S. Moreover, clinical practice. Published evidence is limited, heterogeneous, and insufficient to establish broad efficacy or standard treatment protocols.

📖 Research History

Importantly, HEP-1 research developed from the idea that short ezrin-derived sequences could modify immune-cell signaling or interfere with virus–host interactions involving ERM proteins.

However, much of the clinical literature is regional, uncontrolled, difficult to independently verify, or linked to patent and product-development programs. By contrast, this evidence base should not be treated as equivalent to large, multicenter, peer-reviewed Phase 3 drug trials.

Ezrin Biology and Peptide Origin

What is ezrin?

First, ezrin is a membrane–cytoskeleton linker protein that helps organize microvilli, immune synapses, receptor complexes, cell shape, adhesion, migration, and signaling.

ERM proteins

Next, ezrin, radixin, and moesin share a conserved FERM domain at the N-terminus, a central α-helical region, and a C-terminal actin-binding region. Also, inactive ERM proteins can fold into a closed conformation. Phosphorylation and membrane interactions open the structure and expose binding surfaces.

Why residues 324–337?

Moreover, HEP-1 corresponds to a charged α-helical segment in the central region of ezrin. Consequently, patent descriptions refer to this area as part of a “Hep receptor” or zip-like charged helical structure. This terminology is not a standard receptor classification in modern pharmacology.

Virus–host relevance

Finally, multiple viruses use ERM proteins by multiple viruses during attachment, entry, trafficking, budding, or cell-to-cell spread. However, an ezrin-derived peptide could theoretically compete with viral or host protein interactions, but the exact target may differ across viruses.

🧠 Proposed Mechanism of Action

Importantly, no single receptor or universally accepted molecular mechanism has been established for HEP-1. Therefore, proposed actions include antiviral interference, immune modulation, inflammatory regulation, and effects on ERM-dependent membrane organization.

1. Virus-entry or membrane-complex interference

First, hepatitis C studies suggest that ERM-derived peptides can interfere with virus infection at the cell-surface or post-entry level.

2. Adaptive immune amplification

Moreover, regional clinical literature describes increased adaptive immune responses and altered antibody or lymphocyte activity. For example, independent mechanistic confirmation remains limited.

3. Inflammatory modulation

In addition, researchers have described HEP-1 as reducing excessive inflammatory responses while supporting antiviral immunity. Meanwhile, the balance between immunostimulation and immunosuppression is not fully characterized.

4. Cytoskeletal signaling

Likewise, because the parent protein organizes actin–membrane connections, HEP-1 may alter protein-protein interactions involving ERM-related signaling complexes.

5. Antiviral effects independent of liver repair

Finally, activity against hepatitis viruses would represent antiviral pharmacology, not evidence that the peptide directly regenerates hepatocytes or improves detoxification.

🎯 Target and Pathway Profile

Research Areas

Hepatitis C virus

First, a peer-reviewed study reported that a human radixin-derived peptide and related ERM peptides, including a Hep-1 sequence, inhibited hepatitis C virus infection in cell models. Likewise, these findings support antiviral research but do not establish clinical treatment of chronic hepatitis C.

HIV and opportunistic infections

Next, patents and regional reports originally described HEP-1 in patents and regional clinical reports as an immunomodulator for HIV-associated immune dysfunction and secondary infections. In addition, modern antiretroviral therapy remains the evidence-based standard of care.

Respiratory infections

Moreover, regional reports describe intranasal or topical use for respiratory infections. Moreover, study quality, product characterization, and independent replication vary.

COVID-19

In addition, a randomized clinical study was registered to evaluate HEP-1 in hospitalized SARS-CoV-2-positive patients. By contrast, registration alone does not establish efficacy. Public evidence remains insufficient for routine use.

Gastrointestinal ulcer research

Likewise, patent literature proposed oral HEP-1 for ulcer healing through immune modulation, wound repair, and possible acid-suppression effects. Also, these claims remain outside established ulcer-treatment guidelines.

Post-COVID research

Finally, patent applications proposed HEP-1 for post-COVID symptoms. Consequently, patent claims are not equivalent to validated clinical evidence.

What HEP-1 Does and Does Not Mean for Liver Research

Why the name causes confusion

First, the prefix “HEP” may be mistaken for hepatic or hepatocyte. In HEP-1, it refers to the historical naming of a human ezrin peptide—not an organ-specific liver peptide.

Hepatitis is not the same as hepatocyte regeneration

Moreover, a compound studied against hepatitis C virus can be relevant to liver disease because the virus infects hepatocytes. That does not prove direct liver regeneration, antioxidant defense, detoxification enhancement, or anti-aging activity.

No established detoxification pathway

In addition, no validated evidence shows that HEP-1 directly increases cytochrome P450 function, glutathione conjugation, bile production, ammonia clearance, or other major hepatic detoxification pathways.

No established fibrosis therapy

Finally, HEP-1 is not an approved treatment for fatty liver disease, alcohol-associated liver disease, cirrhosis, fibrosis, hepatitis B, autoimmune hepatitis, or liver failure.

Safety and Regulatory Considerations

Limited standardized human safety data

First, there is no current FDA-approved prescribing information defining dose, route, pharmacokinetics, contraindications, drug interactions, pregnancy safety, or long-term risk.

Immune modulation can be unpredictable

Moreover, a peptide intended to amplify adaptive immunity could theoretically worsen autoimmunity, inflammatory disease, transplant rejection, or cytokine-mediated injury in susceptible individuals.

Highly charged peptide behavior

In addition, HEP-1 may bind nonspecifically to proteins, membranes, nucleic acids, excipients, filters, and container surfaces.

Oral and nasal formulation uncertainty

Likewise, peptide stability, proteolysis, mucosal absorption, local irritation, microbiological quality, and dose uniformity depend on the formulation.

Product-identity risk

However, commercial products called HEP-1 may not match the documented TEKKRRETVEREKE sequence. Exact sequence and terminal forms must be verified.

Regulatory status

Finally, HEP-1 is not FDA approved in the United States. Reports of regional registration or use do not establish U.S. approval, international harmonization, or equivalent manufacturing standards.

🧪 Laboratory Testing Methods

📄 How to Interpret a HEP-1 COA

1. Verify the sequence

First, the documented HEP-1 sequence is TEKKRRETVEREKE.

2. Confirm terminal forms

Next, the standard sequence is generally represented with a free N-terminus and free C-terminal carboxyl group. Acetylated or amidated versions are different compounds.

3. Separate identity, purity, and content

• Identity First, confirms the sequence and molecular mass.
• Purity Next, estimates relative chromatographic composition.
• Net peptide content Also, measures actual HEP-1 after accounting for salts and water.

4. Check counterion burden

Moreover, a highly basic peptide can retain significant trifluoroacetate or other counterions from synthesis and purification.

5. Review route-specific microbiology

In addition, a nasal, oral, topical, or injectable product must be evaluated using standards appropriate to that route. Raw powder purity is not enough.

6. Require functional equivalence before making efficacy claims

Likewise, laboratories should evaluate a chemically correct peptide in a relevant antiviral or immune assay before representing it as equivalent to material used in published studies.

7. Do not infer liver repair from the name

However, a COA confirming HEP-1 does not support claims of hepatocyte regeneration, detoxification, fibrosis reversal, or liver anti-aging.

📊 HEP-1 vs Livagen vs Hepcidin vs Glutathione

Identity and Biological-Role Differences

HEP-1 vs the Original Draft’s Claimed Liver Bioregulator

Evidence-Based Identity Corrections

HEP-1 vs Other ERM-Derived Peptides

🔗 Related Proteins and Pathways

• Ezrin: First, Membrane–actin linker and parent protein of HEP-1.
• Radixin and moesin: Next, Related ERM-family proteins.
• Hepatitis C virus: Also, Major antiviral research context for ERM-derived peptides.
• Actin cytoskeleton: Moreover, Central to ERM protein function.
• Immune synapse: In addition, ERM proteins help organize receptors and cytoskeletal signaling.
• Viral entry and budding pathways: Likewise, Processes in which ERM proteins can participate.

🖼️ Original Diagram Specifications

Diagram 1: HEP-1 sequence and charge map

In addition, Show TEKKRRETVEREKE with acidic residues in one class, basic residues in another, and the free N- and C-termini labeled.

Diagram 2: Ezrin domain structure

Moreover, Show the N-terminal FERM domain, central α-helical region containing residues 324–337, and C-terminal actin-binding region.

Diagram 3: ERM membrane–cytoskeleton linkage

By contrast, Illustrate ezrin connecting membrane proteins to cortical actin and organizing receptor complexes.

Diagram 4: Proposed antiviral mechanism

Also, Show HEP-1 competing with ERM-related virus–host protein interactions at a membrane or intracellular complex. Label the exact target as unresolved.

Diagram 5: Identity correction

Consequently, Use a split graphic contrasting “HEP-1 = human ezrin peptide” with “hepatic bioregulator claim = unsupported.”

Diagram 6: COA workflow

However, Show sequence confirmation, LC-MS identity, HPLC purity, counterion, net content, microbial testing, stability, and functional antiviral assay.

❓ Frequently Asked Questions

Is HEP-1 a peptide?

Therefore, Yes. The documented HEP-1 is a 14-amino-acid synthetic peptide derived from human ezrin.

What is its sequence?

TEKKRRETVEREKE.

Is HEP-1 a liver peptide?

For example, No. The name does not mean hepatic peptide. It refers to Human Ezrin Peptide 1.

What is HEP-1 studied for?

Meanwhile, researchers have studied it for antiviral, anti-inflammatory, and immunomodulatory effects, including hepatitis C and COVID-19 research.

Does HEP-1 regenerate the liver?

Likewise, No validated evidence establishes direct hepatocyte regeneration or liver repair in humans.

Is HEP-1 FDA approved?

No.

Is HEP-1 the same as Gepon?

In addition, Gepon is described in some regional and patent literature as a product containing HEP-1. Product composition and regulatory standards should be verified independently.

Does hepatitis C research prove liver-health benefits?

Moreover, No. Antiviral activity against a liver-tropic virus is not the same as improving detoxification, fibrosis, metabolic liver disease, or liver aging.

Can HEP-1 be taken orally or intranasally?

By contrast, Those routes have appeared in patents and regional reports, but no FDA-approved formulation or standardized U.S. dosing regimen exists.

Does 99% HPLC purity prove effectiveness?

Also, No. It does not establish sequence identity by itself, net content, counterion burden, route-specific safety, antiviral activity, or clinical benefit.

HEP-1 Scientific Overview: Final Thoughts

In conclusion, the original HEP-1 draft was based on an incorrect identity. HEP-1 is not an organ-specific hepatic-repair peptide. It is a 14-amino-acid human ezrin-derived peptide with the sequence TEKKRRETVEREKE.

Moreover, its legitimate research history centers on antiviral and immune-modulating biology, including hepatitis C cell studies, HIV-related development, gastrointestinal patents, and COVID-19 clinical investigation. The evidence base remains limited and does not support broad claims of liver regeneration, detoxification enhancement, fibrosis reversal, or healthy hepatic aging.

Therefore, any HEP-1 product should be evaluated against the documented sequence, terminal chemistry, molecular mass, counterion burden, net peptide content, microbiological quality, stability, and a relevant functional assay. The name alone is not enough to establish identity or benefit.

📚 References

HEP-1, Antiviral, and Clinical-Development Sources

1. For example, Bukong TN, et al. A novel human radixin peptide inhibits hepatitis C virus infection. 2014.
2. Moreover, Holms RD. Ezrin peptide therapy from HIV to COVID. 2021.
3. In addition, ClinicalTrials.gov. Ezrin Peptide HEP-1 for treatment of coronavirus disease.
4. However, European Union Clinical Trials Register. Human Ezrin Peptide 1 as a therapeutic agent for SARS-CoV-2-positive patients. EudraCT 2020-005527-36.
5. Therefore, World Intellectual Property Organization. Ezrin peptide HEP-1 for use in coronavirus disease.
6. Likewise, World Intellectual Property Organization. Ezrin peptide 1 for treating COVID-19.
7. For example, World Intellectual Property Organization. Ezrin peptide 1 for treating post-COVID-19.
8. Moreover, United States Patent. Ezrin-derived peptides and pharmaceutical compositions thereof.
9. In addition, World Intellectual Property Organization. The use of peptides in anti-ulcer therapy.
10. However, World Intellectual Property Organization. WO95/33768. Human ezrin peptide and immune-modulating use.
11. Therefore, World Intellectual Property Organization. WO2004/067024. Ezrin peptides and hepatitis C research.
12. Likewise, MedChemExpress. HEP-1, human ezrin peptide 324–337.
13. For example, Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nature Reviews Molecular Cell Biology. 2010.
14. Moreover, Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nature Reviews Molecular Cell Biology. 2002.

Ezrin Biology, Immunology, and Analytical Sources

15. In addition, McClatchey AI. ERM proteins at a glance. Journal of Cell Science.
16. However, Arpin M, Chirivino D, Naba A, Zwaenepoel I. Emerging role for ERM proteins in cell adhesion and migration. Cell Adhesion & Migration.
17. Therefore, Neisch AL, Fehon RG. Ezrin, radixin and moesin: key regulators of membrane–cortex interactions and signaling. Current Opinion in Cell Biology.
18. Likewise, Tsukita S, Yonemura S. ERM proteins: head-to-tail regulation of actin–plasma membrane interaction. Trends in Biochemical Sciences.
19. For example, Gary R, Bretscher A. Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain. Molecular Biology of the Cell.
20. Moreover, Fievet B, et al. Phosphoinositide binding and phosphorylation regulate ezrin activation. Journal of Cell Biology.
21. In addition, Viswanatha R, Ohouo PY, Smolka MB, Bretscher A. Local phosphocycling mediated by LOK/SLK restricts ezrin function. Journal of Cell Biology.
22. However, Roumier A, et al. Ezrin controls immune synapse morphology and T-cell activation. Immunity-related literature.
23. Therefore, Ilani T, Khanna C, Zhou M, Veenstra TD, Bretscher A. Immune-cell and tumor roles of ezrin. Cancer Research.
24. Likewise, Clucas J, Valderrama F. ERM proteins in cancer progression. Journal of Cell Science.
25. For example, Sato N, et al. ERM proteins and viral infection mechanisms. Virology reviews.
26. Roy NH, Burkhardt JK. The actin cytoskeleton in T-cell activation. Annual Review of Immunology.
27. Delon J, Kaibuchi K, Germain RN. Exclusion of CD43 from the immunological synapse is mediated by ERM proteins. Immunity.
28. International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.
29. United States Pharmacopeia. General Chapter <621>, Chromatography.
30. United States Pharmacopeia. General Chapters <61> and <62>, Microbiological Examination of Nonsterile Products.
31. United States Pharmacopeia. General Chapter <71>, Sterility Tests.
32. United States Pharmacopeia. General Chapter <85>, Bacterial Endotoxins Test.
33. International Council for Harmonisation. ICH Q3C: Impurities—Guideline for Residual Solvents.
34. International Council for Harmonisation. ICH Q6B: Specifications for Biotechnological/Biological Products.
35. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products.

Consequently, Identity, sequence, mechanism, antiviral research, and regulatory status were reviewed in July 2026. HEP-1 remains unapproved in the United States and should not be represented as a validated liver-regeneration peptide.